Successful treatment of post-surgical osteomyelitis caused by XDR pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 9, 2017, Pages 2678-2679

  Gentile, Ivan ^a   Buonomo, Antonio Riccardo ^a   Maraolo, Alberto Enrico ^a   Scotto, Riccardo ^a   De Zottis, Federico ^a   Di Renzo, Gianfranco ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; MEROPENEM; MINOCYCLINE; RIFAMPICIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE DISORDER; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; OFF LABEL DRUG USE; OSTEOMYELITIS; POSTOPERATIVE INFECTION; PSEUDOMONAS AERUGINOSA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECT; FRACTURE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PSEUDOMONAS INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FRACTURES, BONE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OSTEOMYELITIS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 85031015450     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx172     Document Type: Article

References (8)

1. Obritsch MD, Fish DN, MacLaren R et al. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25: 1353-64.
2. Traugott KA, Echevarria K, Maxwell P et al. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 2011; 31: 598-608.
3. Magiorakos AP, SrinivasanA, Carey RB et al.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
4. Gentile I,Maraolo AE, Borgia G.What is the role of the new b-lactam/b-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti Infect Ther 2016; 14: 875-8.
5. Kurtzhalts KE, Mergenhagen KA, Manohar A et al. Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane/tazobactam. BMJ Case Rep 2017; doi: 10.1136/bcr-2016-217005.
6. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54: 393-407.
7. Zhanel GG, Chung P, AdamH et al. Ceftolozane/tazobactam: a novel cephalosporin/ b-lactamase inhibitor combination with activity against multidrugresistant gram-negative bacilli. Drugs 2014; 74: 31-51.
8. Pfaller MA, Bassetti M, Duncan LR et al. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother 2017; 72: 1386-95.